← All trials
NCT03737643
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 4, 2019
- Primary completion
- May 18, 2022
- Completion date
- Jul 28, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 1056
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Myrexis Inc.Collaborator
- European Network for Gynaecological Oncological TrialCollaborator
- European Network for Gynaecological Oncological TrialOverall official - principal investigator
- Gynecologic Oncology GroupOverall official - principal investigator
- GOG Foundation, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.